Company Overview of HUYA Bioscience International, LLC
HUYA Bioscience International, LLC engages in identifying and licensing pre-clinical and clinical stage compounds in China. It engages in accelerating the development of biopharmaceutical product opportunities originating in China. The company offers HBI-8000, a histone deacetylases inhibitors for cancer; HBI-3000, a multi-ion channel blocker for the treatment of arrhythmia; and HBI-3802, a small molecule for improving heart function, as well as stimulates cardiac stem cell differentiation into functional cardiomyocytes, and replaces and remodels dead myocardium with new functional tissues. The company has a strategic alliance with China Wuqing Development Area. HUYA Bioscience International...
12531 High Bluff Drive
San Diego, CA 92130
Founded in 2004
Key Executives for HUYA Bioscience International, LLC
Founder, Executive Chairman, Chief Executive Officer and President
Chief Technology Officer and Chief Operating Officer of Asia
Chief Scientific Officer and Executive Vice President
Head of Therapeutics China
Compensation as of Fiscal Year 2015.
HUYA Bioscience International, LLC Key Developments
Huya Bioscience International Appoints Gloria Tsi-Yie Lee as Chief Medical Officer
Sep 16 15
HUYA Bioscience International announced the expansion of its executive team with the appointment of Gloria Tsi-Yie Lee, M.D., Ph.D., as Chief Medical Officer. Most recently, Dr. Lee was Chief Medical Officer at Beyondspring Pharmaceuticals; she was also the CMO at Kite Pharma. Dr. Lee has more than 20 years of professional experience, with a particular focus on oncology, including clinical development and regulatory strategies and execution of phase I-IV clinical trials that lead to 4 NDAs for several major products in oncology such as taxotere and Zytiga. Her experience also includes franchise development especially in the areas of competitive landscape analysis, and technology assessment.
HUYA Bioscience International Announces Epigenetic Breast Cancer Program
Sep 3 15
HUYA Bioscience International announced expanding clinical trials with its lead cancer drug, HBI-8000, starting with a Phase 1 combination trial in support of a breast cancer program to be conducted in the United States. HBI-8000 is a novel class I-selective oral histone deacetylase (HDAC)Â inhibitor which will be among the first to be included in a clinical trial involving HER2 positive advanced or metastatic cancer patients. The inclusion of HBI-8000 combination therapy for breast cancer as a potential target is a logical extension of the drug's clinical development since it is currently in Phase 1 in Japan for Non-Hodgkin's Lymphoma, has been in several other clinical trials involving solid tumors and is now marketed in China as Epidaza for the treatment of PTCL.
HUYA Bioscience International Announces Appointment of Yoshiki Shimamura as Vice President for Japan Operations
Jun 30 15
HUYA Bioscience International announced an expansion of its Senior Management Team, with the appointment of Yoshiki Shimamura as Vice President for Japan Operations. Mr. Shimamura has more than 25 years of experience in the biopharma industry and clinical research organizations in Japan and South Korea, including companies such as Novocure KK, Hospira Japan Co Ltd, Chong Kun Dang Pharmaceutical Co, Amgen and Taiho Pharmaceutical Co Ltd.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries